These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2307842)

  • 1. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.
    Harada R; Okada N; Fujita T; Okada H
    J Immunol; 1990 Mar; 144(5):1823-8. PubMed ID: 2307842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
    Okada N; Harada R; Fujita T; Okada H
    J Immunol; 1989 Oct; 143(7):2262-6. PubMed ID: 2476502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
    Okada N; Tanaka H; Takizawa H; Okada H
    J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
    Davé SJ; Sodetz JM
    J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
    Hänsch GM; Hammer CH; Vanguri P; Shin ML
    Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5118-21. PubMed ID: 6946459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    Schönermark S; Rauterberg EW; Shin ML; Löke S; Roelcke D; Hänsch GM
    J Immunol; 1986 Mar; 136(5):1772-6. PubMed ID: 2419413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
    Tomlinson S; Whitlow MB; Nussenzweig V
    J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J; Gold D; LoVerde PT; Fishelson Z
    Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
    Okada H; Tanaka H; Okada N
    Eur J Immunol; 1983 Apr; 13(4):340-4. PubMed ID: 6221932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9.
    Boyle MD; Gee AP; Okada M; Borsos T
    J Immunol; 1980 Dec; 125(6):2818-22. PubMed ID: 7430645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
    White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
    J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
    Sher A; Hieny S; Joiner K
    J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
    Brannen CL; Sodetz JM
    Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional properties of the asialo-fifth component of human complement.
    Schultz DR; Arnold PI
    J Immunol; 1990 Jul; 145(2):655-61. PubMed ID: 2114446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
    Schönermark S; Filsinger S; Berger B; Hänsch GM
    Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell-activating monoclonal antibodies, reacting with both leukocytes and erythrocytes, recognize the guinea pig Thy-1 differentiation antigen: characterization and cloning of guinea pig CD90.
    Schäfer H; Bartels T; Hahn G; Otto A; Burger R
    Cell Immunol; 1999 Nov; 197(2):116-28. PubMed ID: 10607429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.